UnknownPhase 2NCT01036659
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Studying Non-histaminic angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bernstein, Jonathan A., M.D.
- Principal Investigator
- Jonathan A. Bernstein, M.D.UC Physicians, Division of Immunology
- Intervention
- ecallantide - Kallikrein inhibitor that blocks the production of bradykinin(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2013
Study locations (3)
- The Jewish Hospital, Cincinnati, Ohio, United States
- Univeristy Hospital, Cincinnati, Ohio, United States
- UC Physicians, Dpt of Internal Medicine, Division of Immunology, Cincinnati, Ohio, United States
Collaborators
Dyax Corp.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01036659 on ClinicalTrials.gov